Indeed, Ozempic and Wegovy may well be in the news in the coming months—if Trump imposes the massive tariffs on Denmark that ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

An estimated 3.4 million Brits meet the criteria to receive a prescription for Wegovy and Mounjaro which would cost ...

We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...